News | May 23, 2011

Positive Clinical Outcomes Reported With Medtronic Corevalve System

May 23, 2011 - A presentation about transcatheter aortic valve implantation (TAVI) at EuroPCR 2011 confirmed positive outcomes in patients receiving the CoreValve System from Medtronic Inc., across seven international clinical registries. The meta-analysis, undertaken by several leading international interventional cardiologists and presented during a late-breaking trial Hot Line session, summarized European data from 2,156 patients treated with the CoreValve System for severe aortic stenosis.

“Our weighted analysis of early and late clinical outcomes after CoreValve implantation demonstrates that this transcatheter self-expandable valve prostheses provides a safe treatment alternative to patients who are at high-risk or unable to undergo surgical aortic valve replacement,” said Carlos E. Ruiz, M.D., Ph.D., director of the structural and congenital heart program at Lenox Hill Heart and Vascular Institute of New York. “There has been some variability in reported early and late outcomes with TAVI systems from individual country registries, which we believe can be attributed to limited sample sizes and different experience levels among physicians.”

The results demonstrate positive patient outcomes based on procedural success rate (97.8 percent), vascular complication rate (2.9 percent), one-month stroke rate (1.9 percent), one-month survival rate (93.8 percent) and one-year all-cause mortality rate from five registries (17.1 percent).

The meta-analysis included findings from Australia, Belgium, France, Germany, New Zealand, Spain and the United Kingdom. Medtronic provided financial support for the meta-analysis. Limitations of the meta-analysis included use of non-standard definitions by independent registries and independent reporting of clinical outcomes.

The CoreValve System is designed to provide a minimally invasive, non-surgical treatment option for patients with symptomatic, severe aortic stenosis who are at high risk, or are ineligible, for open-heart surgery. Worldwide, approximately 300,000 people have been diagnosed with this condition, and approximately one-third of these patients are deemed at too high a risk for open-heart surgery.

Since 2007, the Medtronic CoreValve System has been implanted in more than 40 countries outside the U.S. The Medtronic CoreValve System is currently limited to investigational use in the United States.

For more information:

Related Content

Montreal Heart Institute Performs First Robotic Mitral Valve Surgery
News | Robotic Systems| September 22, 2017
The Montreal Heart Institute (MHI) announced the acquisition of the da Vinci Xi, a new-generation surgical robot, and...
Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study at HFSA 2017
News | Heart Failure| September 21, 2017
MyoKardia Inc. announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study...
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Medtronic Announces Japanese Regulatory Approval for In.Pact Admiral Drug-Coated Balloon
News | Drug-Eluting Balloons| September 13, 2017
Medtronic plc announced that the In.Pact Admiral Drug-Coated Balloon (DCB) received approval from the Japanese Ministry...
Overlay Init